Linezolid resistance in Staphylococcus aureus: an emerging problem

Dr Kiranjeet Kaur; Dr Mandeep Kaur; Dr Amarjit Kaur Gill

Volume : VIII, Issue : XII, December - 2019

Linezolid resistance in Staphylococcus aureus: an emerging problem

Dr Kiranjeet Kaur, Dr Mandeep Kaur, Dr Amarjit Kaur Gill

Abstract :

Background: Linezolid is a precious drug used to treat infections by resistant Gram positive cocci. Resistance to linezolid is either by G2576T mutation or plasmid mediated cfr gene. Aim: This study aimed to find out the prevalence of linezolid resistance among S. aureus. Methods & Materials: The study was conducted in a tertiary care hospital from July 2016 to June 2017. All clinical isolates of S. aureus were subjected to antimicrobial susceptibility testing by Kirby–Bauer disc diffusion method. The confirmed LRSA were included in the study. Clinical details of the patients were analyzed. Results: Out of 162 S. aureus isolates, eight showed resistance for linezolid. Most LRSA strains were isolated from soft tissue infections. Vancomycin showed susceptibility in 87.5% LRSA strains while teicoplanin and tigecycline were 100% susceptible. Conclusion: Linezolid resistance in S. aureus poses a significant challenge in the treatment of infectious diseases. The continued antimicrobial surveillance and stopping injudicious antibiotics use is necessity.